BioEquity Europe 2026

Need for Speed: How Europe Can Compete in the New Era

Globally, innovators are finding the need for speed as the driver for investment, partnering and success: speed to the clinic, speed to early human data, and speed to de-risk assets. The question for European biotechs is what's their best strategy to compete in this arena, facing new momentum from Asia, and an unpredictable landscape in the U.S. As always, the science in Europe is there. There are more experienced operators than ever before. And after four long years, investor sentiment, finally, is turning.

In its 26th edition, Bio€quity Europe travels to Central and Eastern Europe for the first time to explore opportunities in the region, and to debate how European biotech can accelerate to compete — and lead — in today's world.

What Will I Learn?

• How Europe can shorten the path from discovery to the clinic: practical strategies European biotechs can use to accelerate development timelines, rapidly reaching first-in-human data and de-risking assets to attract investors and pharma.
• Where Europe can win as global competition intensifies: a clear-eyed view of how European biotechs can differentiate themselves on the global stage amid rising momentum from Asia and policy and regulatory uncertainty in the U.S.
• Why Central and Eastern Europe matter now: insights into emerging opportunities, talent pools, cost and operational efficiencies, and partnerships from life sciences leaders from the region

Why Should I Attend?

• Debate what is next for the European biotech ecosystem
• Meet VCs, CEOs and BD&L leaders in an intimate setting designed for networking and discussion
• Discover 100+ emerging biotechs selected for the Presenting Company Track
• Schedule partnering meetings with investors and pharma BD&L
• Dive into European biotech trends with an exclusive conference report from Insights Partner McKinsey & Company

More information